Corcept Therapeutics Provides Miricorilant Clinical Development Update
“Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials,” said
“Based on multiple, replicated pre-clinical results as well as on the results of our Phase 1 study in which miricorilant significantly reduced weight gain experienced by healthy volunteers administered olanzapine [
“Miricorilant continues to demonstrate great promise as a treatment for NASH,” added
Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive
Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties include, but are not limited to, our ability to operate our business, conduct our clinical trials and achieve our other goals during the COVID-19 pandemic; risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. These and other risks are set forth in our
In this press release, forward-looking statements include those concerning the development of miricorilant, including its clinical attributes, regulatory approvals, mandates and oversight, and other requirements; our trials involving miricorilant, including their design, results and probability of success. We disclaim any intention or duty to update forward-looking statements made in this press release.
Source: Corcept Therapeutics Incorporated